853 related articles for article (PubMed ID: 24898300)
21. AUTONOMY: the first randomized trial comparing two patient-driven approaches to initiate and titrate prandial insulin lispro in type 2 diabetes.
Edelman SV; Liu R; Johnson J; Glass LC
Diabetes Care; 2014 Aug; 37(8):2132-40. PubMed ID: 24742662
[TBL] [Abstract][Full Text] [Related]
22. Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus.
Jeong IK; Chung CH; Zhou Z; Han JH; Duan R; Edralin DM; Rodriguez A
J Diabetes; 2017 Apr; 9(4):396-404. PubMed ID: 27171584
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
[TBL] [Abstract][Full Text] [Related]
24. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
25. Is insulin the most effective injectable antihyperglycaemic therapy?
Buse JB; Peters A; Russell-Jones D; Furber S; Donsmark M; Han J; MacConell L; Maggs D; Diamant M
Diabetes Obes Metab; 2015 Feb; 17(2):145-51. PubMed ID: 25323312
[TBL] [Abstract][Full Text] [Related]
26. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).
Riddle MC; Forst T; Aronson R; Sauque-Reyna L; Souhami E; Silvestre L; Ping L; Rosenstock J
Diabetes Care; 2013 Sep; 36(9):2497-503. PubMed ID: 23564915
[TBL] [Abstract][Full Text] [Related]
27. Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial.
Nauck M; Horton E; Andjelkovic M; Ampudia-Blasco FJ; Parusel CT; Boldrin M; Balena R;
Diabet Med; 2013 Jan; 30(1):109-13. PubMed ID: 22937895
[TBL] [Abstract][Full Text] [Related]
28. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy.
Rosenstock J; Ahmann AJ; Colon G; Scism-Bacon J; Jiang H; Martin S
Diabetes Care; 2008 Jan; 31(1):20-5. PubMed ID: 17934150
[TBL] [Abstract][Full Text] [Related]
29. Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.
Pantalone KM; Patel H; Yu M; Fernández Landó L
Diabetes Obes Metab; 2018 Jun; 20(6):1461-1469. PubMed ID: 29430801
[TBL] [Abstract][Full Text] [Related]
30. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4.
Blevins T; Pieber TR; Colón Vega G; Zhang S; Bastyr EJ; Chang AM;
Diabetes Obes Metab; 2016 Nov; 18(11):1072-1080. PubMed ID: 27234693
[TBL] [Abstract][Full Text] [Related]
31. Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M; Van Gaal L; Guerci B; Stranks S; Han J; Malloy J; Boardman MK; Trautmann ME
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):464-73. PubMed ID: 24731672
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
[TBL] [Abstract][Full Text] [Related]
33. [Starting an insulin regimen with insulin lispro mix 25 versus glargine insulin for type 2 diabetes].
Fernández Landó L; Massari F; Oviedo A; Jiang H
Medicina (B Aires); 2012; 72(3):235-42. PubMed ID: 22763161
[TBL] [Abstract][Full Text] [Related]
34. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
35. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).
Riddle MC; Bolli GB; Ziemen M; Muehlen-Bartmer I; Bizet F; Home PD;
Diabetes Care; 2014 Oct; 37(10):2755-62. PubMed ID: 25078900
[TBL] [Abstract][Full Text] [Related]
36. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
Trujillo JM; Nuffer W
Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
[TBL] [Abstract][Full Text] [Related]
37. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
[TBL] [Abstract][Full Text] [Related]
39. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
[TBL] [Abstract][Full Text] [Related]
40. Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9).
Pozzilli P; Norwood P; Jódar E; Davies MJ; Ivanyi T; Jiang H; Woodward DB; Milicevic Z
Diabetes Obes Metab; 2017 Jul; 19(7):1024-1031. PubMed ID: 28294499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
